December 16, 2021 Nordic Nanovector appoints Experienced International Life Sciences Executive Sandra Jonsson as Chief Operating Officer
December 15, 2021 Targovax awarded NOK 9.8m research grant by the Research Council of Norway towards the TG mutant RAS program
December 15, 2021 Doctrin makes strategic recruitments to support further expansion – Jesper Eriksson joins as new CFO and Michael Ekelund as CCO
December 14, 2021 HelloBetter Diabetes and Depression – new therapy option for psychologically stressed people with diabetes now available on prescription
December 14, 2021 Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hematology (ASH) Annual Meeting
December 13, 2021 Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting
December 10, 2021 Oncopeptides presents new melflufen data at the Annual American Society of Hematology Meeting ASH
December 09, 2021 Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies
December 06, 2021 Carisma Therapeutics Announces Collaboration with Merck to Evaluate CAR-Macrophages in Combination with KEYTRUDA® (pembrolizumab) in a Clinical Study